Recent  ||| S:0 E:7 ||| JJ
insights  ||| S:7 E:16 ||| NNS
into  ||| S:16 E:21 ||| IN
the  ||| S:21 E:25 ||| DT
pathology  ||| S:25 E:35 ||| NN
of  ||| S:35 E:38 ||| IN
multiple  ||| S:38 E:47 ||| JJ
sclerosis  ||| S:47 E:57 ||| NN
and  ||| S:57 E:61 ||| CC
neuromyelitis  ||| S:61 E:75 ||| FW
optica  ||| S:75 E:82 ||| FW
Multiple  ||| S:82 E:91 ||| FW
sclerosis  ||| S:91 E:101 ||| FW
( ||| S:101 E:102 ||| -LRB-
MS ||| S:102 E:104 ||| NNP
)  ||| S:104 E:106 ||| -RRB-
is  ||| S:106 E:109 ||| VBZ
the  ||| S:109 E:113 ||| DT
most  ||| S:113 E:118 ||| RBS
common  ||| S:118 E:125 ||| JJ
inflammatory  ||| S:125 E:138 ||| JJ
demyelinating  ||| S:138 E:152 ||| JJ
disease  ||| S:152 E:160 ||| NN
of  ||| S:160 E:163 ||| IN
the  ||| S:163 E:167 ||| DT
central  ||| S:167 E:175 ||| JJ
nervous  ||| S:175 E:183 ||| JJ
system ||| S:183 E:189 ||| NN
.  ||| S:189 E:191 ||| .
Traditionally ||| S:191 E:204 ||| RB
,  ||| S:204 E:206 ||| ,
demyelinating  ||| S:206 E:220 ||| JJ
lesions  ||| S:220 E:228 ||| NNS
in  ||| S:228 E:231 ||| IN
the  ||| S:231 E:235 ||| DT
white  ||| S:235 E:241 ||| JJ
matter  ||| S:241 E:248 ||| NN
have  ||| S:248 E:253 ||| VBP
been  ||| S:253 E:258 ||| VBN
regarded  ||| S:258 E:267 ||| VBN
as  ||| S:267 E:270 ||| IN
the  ||| S:270 E:274 ||| DT
most  ||| S:274 E:279 ||| RBS
important  ||| S:279 E:289 ||| JJ
pathological  ||| S:289 E:302 ||| JJ
feature  ||| S:302 E:310 ||| NN
in  ||| S:310 E:313 ||| IN
MS ||| S:313 E:315 ||| NNP
,  ||| S:315 E:317 ||| ,
but  ||| S:317 E:321 ||| CC
recent  ||| S:321 E:328 ||| JJ
pathological  ||| S:328 E:341 ||| NN
and  ||| S:341 E:345 ||| CC
imaging  ||| S:345 E:353 ||| JJ
studies  ||| S:353 E:361 ||| NNS
confirmed  ||| S:361 E:371 ||| VBD
substantial  ||| S:371 E:383 ||| JJ
changes  ||| S:383 E:391 ||| NNS
in  ||| S:391 E:394 ||| IN
grey  ||| S:394 E:399 ||| JJ
matter  ||| S:399 E:406 ||| NN
and  ||| S:406 E:410 ||| CC
normal-appearing  ||| S:410 E:427 ||| JJ
white  ||| S:427 E:433 ||| JJ
matter ||| S:433 E:439 ||| NN
.  ||| S:439 E:441 ||| .
MS  ||| S:441 E:444 ||| NNP
lesions  ||| S:444 E:452 ||| NNS
are  ||| S:452 E:456 ||| VBP
characterized  ||| S:456 E:470 ||| VBN
by  ||| S:470 E:473 ||| IN
inflammation ||| S:473 E:485 ||| NN
,  ||| S:485 E:487 ||| ,
demyelination ||| S:487 E:500 ||| NN
,  ||| S:500 E:502 ||| ,
axonal  ||| S:502 E:509 ||| JJ
damage  ||| S:509 E:516 ||| NN
and  ||| S:516 E:520 ||| CC
astrogliosis ||| S:520 E:532 ||| NN
.  ||| S:532 E:534 ||| .
During  ||| S:534 E:541 ||| IN
early  ||| S:541 E:547 ||| JJ
MS  ||| S:547 E:550 ||| FW
lesion  ||| S:550 E:557 ||| FW
formation  ||| S:557 E:567 ||| FW
acute  ||| S:567 E:573 ||| FW
axonal  ||| S:573 E:580 ||| FW
injury  ||| S:580 E:587 ||| FW
is  ||| S:587 E:590 ||| VBZ
extensive  ||| S:590 E:600 ||| JJ
and  ||| S:600 E:604 ||| CC
correlates  ||| S:604 E:615 ||| NN
with  ||| S:615 E:620 ||| IN
inflammation ||| S:620 E:632 ||| NN
.  ||| S:632 E:634 ||| .
In  ||| S:634 E:637 ||| IN
addition  ||| S:637 E:646 ||| NN
to  ||| S:646 E:649 ||| TO
focal  ||| S:649 E:655 ||| JJ
lesions ||| S:655 E:662 ||| NNS
,  ||| S:662 E:664 ||| ,
diffuse  ||| S:664 E:672 ||| JJ
wide-spread  ||| S:672 E:684 ||| JJ
changes  ||| S:684 E:692 ||| NNS
including  ||| S:692 E:702 ||| VBG
neuroaxonal  ||| S:702 E:714 ||| JJ
degeneration  ||| S:714 E:727 ||| NN
and  ||| S:727 E:731 ||| CC
compartmentalized  ||| S:731 E:749 ||| JJ
inflammation  ||| S:749 E:762 ||| NNS
are  ||| S:762 E:766 ||| VBP
likely  ||| S:766 E:773 ||| JJ
to  ||| S:773 E:776 ||| TO
contribute  ||| S:776 E:787 ||| VB
to  ||| S:787 E:790 ||| TO
increasing  ||| S:790 E:801 ||| VBG
disability  ||| S:801 E:812 ||| NN
in  ||| S:812 E:815 ||| IN
progressive  ||| S:815 E:827 ||| JJ
MS ||| S:827 E:829 ||| NNP
.  ||| S:829 E:831 ||| .
Neuromyelitis  ||| S:831 E:845 ||| JJ
optica  ||| S:845 E:852 ||| NNS
( ||| S:852 E:853 ||| -LRB-
NMO ||| S:853 E:856 ||| NNP
)  ||| S:856 E:858 ||| -RRB-
is  ||| S:858 E:861 ||| VBZ
classically  ||| S:861 E:873 ||| VBN
characterized  ||| S:873 E:887 ||| VBN
by  ||| S:887 E:890 ||| IN
severe  ||| S:890 E:897 ||| JJ
transverse  ||| S:897 E:908 ||| JJ
myelitis  ||| S:908 E:917 ||| NN
and  ||| S:917 E:921 ||| CC
optic  ||| S:921 E:927 ||| JJ
neuritis ||| S:927 E:935 ||| NN
,  ||| S:935 E:937 ||| ,
but  ||| S:937 E:941 ||| CC
brain  ||| S:941 E:947 ||| NN
lesions  ||| S:947 E:955 ||| NNS
are  ||| S:955 E:959 ||| VBP
also  ||| S:959 E:964 ||| RB
present  ||| S:964 E:972 ||| VB
in  ||| S:972 E:975 ||| IN
the  ||| S:975 E:979 ||| DT
majority  ||| S:979 E:988 ||| NN
of  ||| S:988 E:991 ||| IN
NMO  ||| S:991 E:995 ||| NNP
patients ||| S:995 E:1003 ||| NNS
.  ||| S:1003 E:1005 ||| .
The  ||| S:1005 E:1009 ||| DT
discovery  ||| S:1009 E:1019 ||| NN
of  ||| S:1019 E:1022 ||| IN
the  ||| S:1022 E:1026 ||| DT
NMO-specific  ||| S:1026 E:1039 ||| JJ
antibody  ||| S:1039 E:1048 ||| NN
demonstrated  ||| S:1048 E:1061 ||| VBN
that  ||| S:1061 E:1066 ||| IN
NMO  ||| S:1066 E:1070 ||| NNP
is  ||| S:1070 E:1073 ||| VBZ
a  ||| S:1073 E:1075 ||| DT
disease  ||| S:1075 E:1083 ||| NN
entity  ||| S:1083 E:1090 ||| NN
distinct  ||| S:1090 E:1099 ||| NN
from  ||| S:1099 E:1104 ||| IN
MS ||| S:1104 E:1106 ||| NNP
.  ||| S:1106 E:1108 ||| .
This  ||| S:1108 E:1113 ||| DT
antibody  ||| S:1113 E:1122 ||| NN
binds  ||| S:1122 E:1128 ||| NN
to  ||| S:1128 E:1131 ||| TO
aquaporin-4  ||| S:1131 E:1143 ||| NNP
expressed  ||| S:1143 E:1153 ||| VBD
in  ||| S:1153 E:1156 ||| IN
astrocytes  ||| S:1156 E:1167 ||| NN
and  ||| S:1167 E:1171 ||| CC
ependymal  ||| S:1171 E:1181 ||| JJ
cells ||| S:1181 E:1186 ||| NNS
.  ||| S:1186 E:1188 ||| .
NMO  ||| S:1188 E:1192 ||| NNP
lesions  ||| S:1192 E:1200 ||| NNS
are  ||| S:1200 E:1204 ||| VBP
characterized  ||| S:1204 E:1218 ||| VBN
by  ||| S:1218 E:1221 ||| IN
inflammation ||| S:1221 E:1233 ||| NN
,  ||| S:1233 E:1235 ||| ,
demyelination ||| S:1235 E:1248 ||| NN
,  ||| S:1248 E:1250 ||| ,
axonal  ||| S:1250 E:1257 ||| JJ
damage  ||| S:1257 E:1264 ||| NN
and  ||| S:1264 E:1268 ||| CC
a  ||| S:1268 E:1270 ||| DT
marked  ||| S:1270 E:1277 ||| JJ
loss  ||| S:1277 E:1282 ||| NN
of  ||| S:1282 E:1285 ||| IN
aquaporin-4 ||| S:1285 E:1296 ||| CD
.  ||| S:1296 E:1298 ||| .
Early  ||| S:1298 E:1304 ||| RB
NMO  ||| S:1304 E:1308 ||| JJ
lesions  ||| S:1308 E:1316 ||| NNS
demonstrate  ||| S:1316 E:1328 ||| VBP
a  ||| S:1328 E:1330 ||| DT
pronounced  ||| S:1330 E:1341 ||| JJ
humoral  ||| S:1341 E:1349 ||| JJ
inflammatory  ||| S:1349 E:1362 ||| JJ
response  ||| S:1362 E:1371 ||| NN
and  ||| S:1371 E:1375 ||| CC
astrocytic  ||| S:1375 E:1386 ||| JJ
cell  ||| S:1386 E:1391 ||| NN
death  ||| S:1391 E:1397 ||| NN
with  ||| S:1397 E:1402 ||| IN
loss  ||| S:1402 E:1407 ||| NN
of  ||| S:1407 E:1410 ||| IN
aquaporin-4 ||| S:1410 E:1421 ||| NNP
,  ||| S:1421 E:1423 ||| ,
followed  ||| S:1423 E:1432 ||| VBN
by  ||| S:1432 E:1435 ||| IN
inflammatory  ||| S:1435 E:1448 ||| JJ
demyelination  ||| S:1448 E:1462 ||| NN
and  ||| S:1462 E:1466 ||| CC
axonal  ||| S:1466 E:1473 ||| JJ
damage ||| S:1473 E:1479 ||| NN
.  ||| S:1479 E:1481 ||| .
These  ||| S:1481 E:1487 ||| DT
recent  ||| S:1487 E:1494 ||| JJ
findings  ||| S:1494 E:1503 ||| NNS
contribute  ||| S:1503 E:1514 ||| VBP
to  ||| S:1514 E:1517 ||| TO
a  ||| S:1517 E:1519 ||| DT
better  ||| S:1519 E:1526 ||| JJR
understanding  ||| S:1526 E:1540 ||| NN
of  ||| S:1540 E:1543 ||| IN
different  ||| S:1543 E:1553 ||| JJ
mechanisms  ||| S:1553 E:1564 ||| NNS
leading  ||| S:1564 E:1572 ||| VBG
to  ||| S:1572 E:1575 ||| TO
inflammatory  ||| S:1575 E:1588 ||| JJ
demyelination ||| S:1588 E:1601 ||| NN
.  ||| S:1601 E:1603 ||| .
